Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98,567,360
-
Number of holders
-
95
-
Total 13F shares, excl. options
-
66,513,560
-
Shares change
-
+11,672,675
-
Total reported value, excl. options
-
$251,422,250
-
Value change
-
+$40,292,023
-
Put/Call ratio
-
41.59%
-
Number of buys
-
57
-
Number of sells
-
-39
-
Price
-
$3.78
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q3 2023
123 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 95 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66,513,560 shares
of 98,567,360 outstanding shares and own 67.48% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (11,077,927 shares), RA CAPITAL MANAGEMENT, L.P. (9,459,678 shares), ORBIMED ADVISORS LLC (9,240,887 shares), Charles Schwab Trust Co (4,246,071 shares), SR ONE CAPITAL MANAGEMENT, LP (4,012,903 shares), FRANKLIN RESOURCES INC (3,868,509 shares), BlackRock Inc. (2,566,784 shares), K2 PRINCIPAL FUND, L.P. (2,552,062 shares), VANGUARD GROUP INC (2,121,289 shares), and BAKER BROS. ADVISORS LP (2,006,451 shares).
This table shows the top 95 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.